tiprankstipranks
Marker Therapeutics’ MT-601 Shows Promising Results
Company Announcements

Marker Therapeutics’ MT-601 Shows Promising Results

Marker Therapeutics (MRKR) has released an update.

Don't Miss Our New Year's Offers:

Marker Therapeutics, Inc. has made a significant breakthrough in its Phase 1 APOLLO study, with their MT-601 treatment showing promising results in patients with lymphoma who have relapsed from or are ineligible for anti-CD19 CAR T cell therapy. One patient achieved a complete response for over nine months, surpassing previous therapies, while two others also showed positive responses, including complete and partial remissions. These results, presented at the 11th Global Summit on Hematologic Malignancies, suggest MT-601 could be a durable alternative for lymphoma treatment.

For further insights into MRKR stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyMarker Therapeutics sells 5.03M shares at $3.20 in private placement
TheFlyMarker Therapeutics provides update on MT-601 patients
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App